USPSTF recommends aspirin for prevention of colorectal cancer
the ONA take:
For the first time, the United States Preventive Services Task Force (USPSTF) has issued a broad recommendation to take aspirin to prevent colorectal cancer.
In the draft report, the task force found that low-dose or baby aspirin can help prevent heart attacks, stroke, and colorectal cancer, particularly in high-risk people in their 50’s.
An analysis on colorectal cancer found that aspirin use reduced colorectal cancer-related deaths by 33% and reduced colon cancer incidence by 40%; however, people need to take aspirin for at least 5 to 10 years in order to have a benefit.
“No major health organization has previously recommended the use of aspirin to prevent cancer,” Dr. Eric Jacobs of the American Cancer Society said. “This is a new approach that makes a great deal of sense.”
However, not everyone feels positively about these new recommendations. “People still need to be screened,” Dr. David Johnson of the United Stated Multi-Society Task Force on Colorectal Cancer said. “I have major reservations that the message will be, ‘I take aspirin, so I don’t need to be screened.’”
According to the American Cancer Society, colorectal cancer is the third leading cause of cancer-related deaths in the United States in men and women separately and the second leading cause when combined.
The USPSTF has issued a broad recommendation to take aspirin to prevent colorectal cancer.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Pediatric Hepatocellular Carcinoma: Challenges and Solutions
- Earlier and Later Adult BMI Associated With Multiple Myeloma Risk
- Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated
- VBPWPs Can Compliment Patient Management in Clinical Trials
- Communication Technology Improves Treatment Burden, Patient Perspective of Oncology Care
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|